Literature DB >> 33531597

Central serous chorioretinopathy in active endogenous Cushing's syndrome.

Joost Brinks1, Femke M van Haalen2, Thomas J van Rijssen1, Nienke R Biermasz2, Onno C Meijer2, Alberto M Pereira2, Camiel J F Boon1,3, Elon H C van Dijk4.   

Abstract

Multiple case series have provided evidence for a relatively high incidence of central serous chorioretinopathy (CSC) in patients with active Cushing's syndrome (CS). We describe the ophthalmological status in detail of consecutive patients with active endogenous CS (either de novo or recurrent active endogenous CS) in this prospective cohort study. All patients underwent complete ophthalmological examination, including multimodal imaging, which was performed shortly after establishing the diagnosis of active CS in hypercortisolemic state. Eleven CS patients (4 men, 7 women) with active hypercortisolism were included. Abnormalities reminiscent of (subclinical) CSC were found in 3 patients. Optical coherence tomography (OCT) revealed macular subretinal fluid in 1 patient, who was diagnosed as having active CSC and was successfully treated with half-dose photodynamic therapy. Two other patients showed CSC-like abnormalities: an unilateral pseudovitelliform lesion on OCT and hyperfluorescent changes on fluorescein angiography in one patient, and unilateral leakage on fluorescein angiography in the other patient. Mean subfoveal choroidal thickness on enhanced depth imaging OCT was 270 ± 40 μm (range, 178 - 357 μm). Retinal abnormalities resembling (subclinical) CSC may be more common than previously thought in patients with active CS, and may exist even in patients without visual complaints. Clinicians should have a low threshold for ophthalmological evaluation in case of a CS patient with visual symptoms since there may be therapeutic opportunities to prevent vision loss.

Entities:  

Year:  2021        PMID: 33531597     DOI: 10.1038/s41598-021-82536-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  16 in total

1.  Intravitreal triamcinolone acetonide and central serous chorioretinopathy.

Authors:  J B Jonas; B A Kamppeter
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

2.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 3.  Cushing's syndrome: update on signs, symptoms and biochemical screening.

Authors:  Lynnette K Nieman
Journal:  Eur J Endocrinol       Date:  2015-07-08       Impact factor: 6.664

4.  Central serous chorioretinopathy: a personal perspective.

Authors:  Lawrence A Yannuzzi
Journal:  Am J Ophthalmol       Date:  2010-03       Impact factor: 5.258

Review 5.  Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis.

Authors:  Alejandra Daruich; Alexandre Matet; Ali Dirani; Elodie Bousquet; Min Zhao; Nicolette Farman; Frédéric Jaisser; Francine Behar-Cohen
Journal:  Prog Retin Eye Res       Date:  2015-05-27       Impact factor: 21.198

6.  Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission.

Authors:  John R Lindsay; Tonya Nansel; Smita Baid; Julie Gumowski; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2005-11-08       Impact factor: 5.958

Review 7.  Central serous chorioretinopathy: a review of epidemiology and pathophysiology.

Authors:  Gerald Liew; Godfrey Quin; Mark Gillies; Samantha Fraser-Bell
Journal:  Clin Exp Ophthalmol       Date:  2012-09-21       Impact factor: 4.207

8.  Central serous chorioretinopathy as a presenting symptom of endogenous Cushing syndrome: a case report.

Authors:  Ludovico Iannetti; Giovanni Spinucci; Francesca Romana Pesci; Roberto Vicinanza; Antonio Stigliano; Paola Pivetti-Pezzi
Journal:  Eur J Ophthalmol       Date:  2011 Sep-Oct       Impact factor: 2.597

Review 9.  Central serous chorioretinopathy: Towards an evidence-based treatment guideline.

Authors:  Thomas J van Rijssen; Elon H C van Dijk; Suzanne Yzer; Kyoko Ohno-Matsui; Jan E E Keunen; Reinier O Schlingemann; Sobha Sivaprasad; Giuseppe Querques; Susan M Downes; Sascha Fauser; Carel B Hoyng; Felice Cardillo Piccolino; Jay K Chhablani; Timothy Y Y Lai; Andrew J Lotery; Michael Larsen; Frank G Holz; K Bailey Freund; Lawrence A Yannuzzi; Camiel J F Boon
Journal:  Prog Retin Eye Res       Date:  2019-07-15       Impact factor: 21.198

10.  Chronic central serous chorioretinopathy as a presenting symptom of Cushing syndrome.

Authors:  Elon H C van Dijk; Greet Dijkman; Nienke R Biermasz; Femke M van Haalen; Alberto M Pereira; Camiel J F Boon
Journal:  Eur J Ophthalmol       Date:  2016-04-22       Impact factor: 2.597

View more
  2 in total

1.  The Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathy.

Authors:  Joost Brinks; Elon H C van Dijk; Szymon M Kiełbasa; Hailiang Mei; Isa van der Veen; Hendrika A B Peters; Hetty C M Sips; Robbert G E Notenboom; Paul H A Quax; Camiel J F Boon; Onno C Meijer
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 5.958

Review 2.  Pachychoroid Spectrum Diseases in Patients with Cushing's Syndrome: A Systematic Review with Meta-Analyses.

Authors:  Jeppe K Holtz; Janni M E Larsson; Michael S Hansen; Elon H C van Dijk; Yousif Subhi
Journal:  J Clin Med       Date:  2022-07-29       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.